Puma Biotechnology, Inc. insider trading
Every open-market purchase and sale by Puma Biotechnology, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Puma Biotechnology, Inc.’s insiders pay?
From April 26, 2012 to November 13, 2025, 18 insiders reported 17 open-market purchases and 54 sales not made under a pre-set plan in Puma Biotechnology, Inc. Twelve months after each purchase was reported, the shares were +257.3% against the S&P 500 on average (median +263.6%), over 17 purchases with a full year of prices; 100% beat the index. After sales, the shares moved −59.4% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 27, 2012 into $238,140 by November 2, 2026, +24.5% a year. It held shares 18% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,793 (+4.8% a year), and held throughout $69,226 (+14.3%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Auerbach Alan H | President and CEO | 0 | — | — | 20 | −65.4% (17) | January 5, 2023 |
| Adage Capital Partners, L.P. | 10% owner | 6 | +296.9% (6) | 100% | 1 | −54.9% (1) | June 5, 2017 |
| Adage Capital Partners Gp, L.L.C. | 10% owner | 4 | +316.6% (4) | 100% | 2 | −49.0% (2) | June 12, 2017 |
| Hunt Douglas M | See Remarks | 0 | — | — | 6 | −34.7% (4) | January 5, 2023 |
| Miller Michael Patrick | Director | 0 | — | — | 5 | — | November 13, 2025 |
| Nougues Maximo F | Chief Financial Officer | 0 | — | — | 4 | −100.3% (1) | January 5, 2023 |
| Bryce Richard Paul | SEE REMARKS | 0 | — | — | 3 | −59.8% (3) | January 6, 2021 |
| Ludwig Jeffrey Jerome | Chief Commercial Officer | 0 | — | — | 3 | — | January 5, 2023 |
| Malley Thomas | Director | 3 | +161.3% (3) | 100% | 0 | — | October 25, 2012 |
| Moyes Jay M | Director | 0 | — | — | 3 | −57.5% (3) | June 11, 2021 |
| Gross Phillip | 10% owner | 2 | +94.2% (2) | 100% | 0 | — | October 22, 2012 |
| Senderowicz Adrian | Director | 0 | — | — | 2 | −44.4% (2) | June 15, 2021 |
| Wilson Troy Edward | Director | 0 | — | — | 2 | −46.3% (2) | June 11, 2021 |
| Adage Capital Advisors, L.L.C. | 10% owner | 1 | +389.3% (1) | 100% | 0 | — | December 14, 2012 |
| Atchinson Robert | 10% owner | 1 | +263.6% (1) | 100% | 0 | — | July 27, 2012 |
| Eyler Charles R | SEE REMARKS | 0 | — | — | 1 | −94.4% (1) | January 4, 2019 |
| Miller Ann Calby | Director | 0 | — | — | 1 | −65.2% (1) | June 11, 2021 |
| Wong Alvin F | Chief Scientific Officer | 0 | — | — | 1 | — | January 5, 2023 |
When several insiders traded Puma Biotechnology, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Puma Biotechnology, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +11.9% against the index. After 5 selling crowds, −41.2%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 30, 2021 | 5 selling | −25.2% | −78.6% | −58.3% |
| January 29, 2021 | 4 selling | −29.1% | −55.2% | −101.6% |
| June 30, 2020 | 3 selling | −11.9% | −24.3% | −52.9% |
| January 31, 2020 | 3 selling | +32.2% | +28.6% | +35.2% |
| January 31, 2019 | 3 selling | +9.3% | −76.5% | −93.3% |
| November 29, 2013 | 2 buying | +135.5% | +3.6% | +319.0% |
| April 30, 2012 | 2 buying | −3.5% | +20.1% | +122.5% |